Will Offshore Tax Havens Face More Scrutiny in 2014?
Standard and Poors says offshore tax havens will face tighter regulation in 2014. Could stocks be affected?
Two Years Less Exclusivity Is the Least of Amarin's Issues
Amarin's patents holding up in court and being able to compete with GlaxoSmithKline's Lovaza for patients are much bigger deals.
Monday’s Winners and Losers: Celsion Corporation, Celladon Corp, and Amarin Corporation plc
Celsion and Celladon Corp scored wins in the health-care space today, while Amarin gets some bad news.
Amarin Given 3-Year Exclusivity for Vascepa
Amarin is granted exclusivity from the FDA, but was hoping for a longer term.
3 Biotech Stocks to Avoid: Amarin, Dendreon, and Prosensa
Amarin, Dendreon, and Prosensa are three biotech stocks which should be avoided at all costs. Here’s why.